Clinical trial NCT06345677: Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects
Official title: An Exploratory, Prospective, Multicenter, Randomized, Double Blind, Placebo + Sham Device Controlled, Study to Assess the Safety, Usability, and Initial Efficacy of the ViXe Combination for Intravesical Administration of XEOMIN® in the Treatment of Female Patients With Idiopathic Overactive Bladder (OAB)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overactive Bladder
Lead sponsor: Vensica Therapeutics Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Blueclinical, Ltd.
First posted: 2024-04-03
Enrollment: 48
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this interventional clinical trial is to assess the safety, usability and initial efficacy of Xeomin and Vibe combination (ViXe) compared to placebo + sham in female subjects with idiopathic Overactive Bladder. The main question\[s\] it aims to answer are: • The rate of device and drug related serious adverse events during treatment and throughout the follow up period • Investigator, subject and technician satisfaction from treatment, and • Assess the initial efficacy of the drug-device combination compared to placebo-sham combination. Participants will be treated a single time with the ViXe combination and will be followed up for a period of 12 weeks, during which they will visit the clinic after 2, 6 and 12 weeks. Participants will complete a 3-day voiding diary prior to the 6- and 12-week FU visit.


Eligibility criteria: Inclusion Criteria:

* Female aged between 18 and 80 years at the time of signing the informed consent.
* Signed written informed consent.
* Diagnosis of OAB for at least 6 months prior to screening, determined by documented subject history.
* At least 8 voiding episodes/day based on 3-consecutive days voiding diary at screening.
* OAB with at least 6 leaking episodes associated with urgency (UUI), and at least one episode per day demonstrated on 3-consecutive days voiding diary.
* Subject is mentally competent with the ability to understand and comply with the requirements of the study.
* Subject is willing and able to initiate self-catheterization post treatment, if required.
* Subject with inadequate response to conservative medication treatment/s as defined by the investigator.
* Subject agrees to attend all follow-up evaluations and is willing and capable to fill out voiding diaries and questionnaires completely and accurately and is willing to complete required exams and tests.
* Females with childbearing potential must have a negative pregnancy test and must practice an acceptable method of birth control, from at least 4 weeks before treatment until 12 weeks after treatment

Exclusion Criteria:

* Previous participation in another study with any investigational drug or device within the past 90 days.
* Allergy to Botulinum neurotoxin type A or any of the other ingredients and components of this device or the drug
* Subject with OAB caused by neurological conditions (i.e., Myasthenia Gravis, ALS, Eaton-Lambert Syndrome, etc.)
* Any neurological disease or disorder including Alzheimer's, Parkinson, MS, stroke (CVA), neuropathy or injury resulting in neuropathy.
* Subject currently under treatment with biofeedback, pelvic muscle rehabilitation, pelvic floor physical therapy. If willing to discontinue will be allowed to participate after 4 weeks of wash out. Self-Kegels exercises are allowed.
* Bleeding disorders or treatment with anticoagulants, antiplatelet (except acetylsalicylic acid), or thrombolytic medications within 14 days prior to screening.
* Subjects with compromised respiratory function or dysphagia.
* Current or planned treatment with drugs that interfere with neuromuscular transmission (e.g., aminoglycoside, polypeptide antibiotics, lincomycin antibiotics, or aminoquinolines)
* Subject with known polyuria/polydipsia with 24-hour total volume void \> 3000 ml.
* Subject with PVR ≥ 200 ml based on bladder ultrasound at screening visit.
* Current or recurrent urinary tract infection (3 or more infections in the last 6 months), or presence of urinary fistula per physical examination, or known significant urinary tract obstruction or urethral stricture.
* Subject who received botulinum toxin injections within the past 8 months.
* Subject with predominant stress incontinence based on MESA incontinence score and/or voiding diary at screening.
* BMI ≥ 35 kg/m2.
* If used, should be on stable doses of diuretics for the past 3 months.
* Subjects who have any implanted electronic devices (a pacemaker, for example), permanent or transient, that cannot be removed prior to the treatment.
* Subjects who have received tibial or sacral nerve stimulation (SNS) any time in the past or percutaneous tibial nerve (PTNS) in the last 3 months.
* Previous urinary incontinence surgery or prolapse surgery or de novo urinary incontinence post-surgery within the last 12 months.
* Any spinal surgery within the last 12 months.
* Previous abdominoperineal resection of the rectum or previous radical hysterectomy.
* Diagnosis of interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines.
* History of evidence of anatomic pelvic, urological or urogenital abnormality according to investigator's discretion.
* If used, subjects should be on stable dose of antimuscarinics and/or beta-3 adrenergic agonists for at least 3 months prior to enrolment and agree to remain on stable medication consumption until the 12-weeks follow-up visit.
* If used, subjects should be on a stable dose of tricyclic antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) for at least 3 months prior to enrolment and agree to remain on stable medication consumption until the 12 weeks follow-up visit.
* Subject with abnormal renal function defined by estimated glomerular filtration rate (eGFR) of 30 ml/min or less.
* History of pelvic radiotherapy or chemotherapy for pelvic malignancies.
* Diabetes with peripheral nerve neuropathy or severe uncontrolled diabetes (with HbA1C \> 7.5%).
* Uterine prolapse, cystocele, enterocele or rectocele past the hymen.
* Deemed unsuitable for enrollment by the investigator based on history or physical examination.
* Any psychiatric or personality disorder at the discretion of the study physician.
* Any severe or uncontrolled systemic disease (e.g., cardiac, renal, pulmonary, hepatic, or gastrointestinal), malignant tumor, or medical history of HIV infection, or any findings from laboratory or physical examination performed at screening at the discretion of the investigator
* Subject is breastfeeding
* Drug or alcohol abuse

Primary outcomes:
measure: Adverse Events Rate
timeFrame: 12 weeks
measure: Usability and ease-of-use perception by investigator, subject and technician
timeFrame: Procedure
Secondary outcomes:
measure: Daily Urgency Urinary Incontinence
timeFrame: 12 weeks
measure: Total Daily Episodes
timeFrame: 12 weeks
measure: Urinary Urgency
timeFrame: 12 weeks
measure: Voiding Leaks
timeFrame: 12 weeks
measure: Quality of Life Queationnsaire
timeFrame: 12 weeks
measure: Nocturia
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Coimbra
country: Portugal
facility: CHUC
city: Guimarães
country: Portugal
facility: HSOG
city: Lisboa
country: Portugal
facility: CHLN
city: Porto
country: Portugal
facility: CHUSJ
city: Porto
country: Portugal
facility: Hospital Lusíadas
city: Porto
country: Portugal
facility: Hospital Prelada
city: Setúbal
country: Portugal
facility: Hospital Luz Setúbal
city: Vila Nova De Gaia
country: Portugal
facility: CHVNG
Study officials:
affiliation: Principal investigator at CHLN
name: Palma dos Reis, Dr
role: PRINCIPAL_INVESTIGATOR
References: